Kala - KALA

Kala Bio Stock (NASDAQ:KALA), Trade Ideas

Kala Pharmaceuticals

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

News

Penny Stocks

Small Cap

Trading Ideas

$BTC

AGLE

AIRS

APLM

BFRG

GFAI

GREE

KALA

RAIN

TORO

VCIG

BRFG

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move.

High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.

10 Short Squeeze Stocks To Watch: Aeglea Biotherapeutics, Toro Corp, AirSculpt, A Company Moves Up 4,166 Positions &amp; More

ELEV

GETY

INAB

LUNR

MLTX

MULN

PXMD

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move.

High-short interest and high-cost to borrow are among the common traits that could lead to a short squeeze.

10 Short Squeeze Stocks To Watch: Toro Corp, PaxMedica, Getty Images And More

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move.

High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.

5 Short Squeeze Stocks To Watch: Getty Images, Bullfrog AI And A New Leader For The Week

Kala Bio Inc

KALAMAZOO RESOURCES by KALAMAZOO RESOURCES LTD.

Kalamazoo Resources Ltd

Kalao

The 12 jurors who will decide the fate of former President Donald Trump were selected in the highly anticipated criminal trial involving alleged <a href="https://www.benzinga.com/general/politics/24/04/38251447/trump-hush-money-trial-preview-key-witnesses-2024-campaign-impact-prison-time-trump-could-face-i">hush money payments.</a>
Here are the latest details and what comes next.
What Happened: A lengthy process that saw <a href="https://www.benzinga.com/general/social-media/24/04/38282616/trump-trial-gets-7-jurors-11-to-go-their-old-social-media-posts-take-center-stage-in-court-e">hundreds of potential jurors</a> asked about their necessity to be impartial in the trial against Trump is one step closer to the trial beginning.
On Thursday, jurors seated for the hush money case now stands at 12, the total needed for the verdict, as <a href="https://www.nbcnews.com/politics/donald-trump/live-blog/trump-hush-money-trial-day-3-live-updates-rcna145936">shared </a>by NBC News.
Making up the jury are seven men and five women. Here are the jurors and their professions, as <a href="https://www.nbcnews.com/politics/donald-trump/meet-the-first-7-jury-members-as-trumps-hush-money-trial-progresses-rcna148198">reported </a>by NBC News. 
<ol>
<li>Male, works in sales</li>
<li>Male, investment banking</li>
<li>Male, attorney</li>
<li>Male, security engineer</li>
<li>Female, teacher</li>
<li>Female, software engineer</li>
<li>Male, attorney, likes the outdoors</li>
<li>Male, retired, previously worked in wealth management</li>
<li>Female, speech therapist</li>
<li>Male, commerce worker</li>
<li>Female, product development manager</li>
<li>Female, physical therapist</li>
</ol>
"We have our jury," Judge Juan Merchan said after a 12th juror was agreed upon by the prosecution and defense.
Merchan gave instructions to the jurors Thursday before they left, reminding them that they cannot discuss the case. The judge reminded the jurors that they are expected to view the case with a "fair and impartial manner."
Getting to 12 jurors Thursday could come as a surprise after the way the court day began. After reaching seven jurors Tuesday before adjourning the trial until Thursday, two of the jurors were removed early Thursday.
One juror was dismissed after a prior arrest was brought into question.
Juror 2, an oncology nurse, was excused earlier in the day after saying that after sleeping on the case, she worried she could no longer be impartial. She also was concerned about her identity becoming public with family already asking if she was on the jury.
The jury selection process has also seen large numbers of potential jurors dismissed after saying they can't be impartial in the case. When Merchan asked a pool of 96 potential jurors to raise their hand if they can't be impartial in the case, 48 were immediately dismissed.
Related Link: <a href="https://www.benzinga.com/general/politics/24/04/38261008/donald-trump-argues-political-prosecution-before-jury-selection-in-new-york-trial-judge-not-goin">Donald Trump Argues &#8216;Political Prosecution&#8217; Before Jury Selection In New York Trial: &#8216;Judge Not Going To Allow Me To Escape This Scam&#8217;</a>
What's Next: Six additional jurors are still needed, who will serve as alternates.
The plan, as of now, is for the trial to begin Monday. This could happen if the alternates are selected on Friday. "I'm hopeful we will finish tomorrow," Merchan said.
Trump's hush money criminal trial is expected to last six to eight weeks.
Speaking to reporters after the case wrapped Thursday, Trump said he should have been campaigning in key states for the 2024 election.
"I've been here all day," Trump said.
Trump called the case an "unfair trial."
"The whole thing is a mess."
DJT Price Action: Shares of Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) have been volatile during Trump's legal proceedings.
Shares spiked Thursday, but it was likely unrelated to the case. The<a href="https://www.benzinga.com/markets/equities/24/04/38319481/why-trump-media-technology-group-shares-are-gaining-thursday"> shares traded higher </a>after a filing from the company explained to shareholders how to keep the shares they own from being loaned out for short selling.
DJT shares closed Thursday up 25.72% to $33.19 versus a 52-week trading range of $22.55 to $79.38.
Read Next: <a href="https://www.benzinga.com/general/politics/24/04/38279176/trump-hush-money-trial-draws-reaction-from-congressman-talk-show-hosts-worse-than-anything-richa">Trump Hush Money Trial Draws Reaction From Congressman, Talk Show Hosts: &#8216;Worse Than Anything Richard Nixon Ever Did&#8217;</a>
Photo: Created with artificial intelligence on MidJourney and Zolnierek on Shutterstock

Politics

Legal

Trump Hush Money Trial Has 12 Jurors: Here Are The 7 Men, 5 Women To Decide Former President's Fate

Two of the greatest and most well-known movie directors of the past 50 years are teaming up on a new series. Here's what Martin Scorsese and Steven Spielberg are up to and how it could help<a href="https://www.benzinga.com/topic/streaming-stocks"> a streaming company.</a>
What Happened: Scorsese and Spielberg are uniting to serve as executive producers on a "Cape Fear" series. The series, which is based on 1962 and 1991 films will <a href="https://www.benzinga.com/topic/apple-tv-0">stream on AppleTV+</a>, a unit of Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). 
It is unknown if Scorsese or Spielberg will direct or write the series, or both will simply serve as producers on the project. The news was reported by <a href="https://variety.com/2024/film/news/martin-scorsese-frank-sinatra-biopic-dicaprio-jennifer-lawrence-1235973769/">Variety</a>. 
Starring Nick Nolte and Robert De Niro, the 1991 film grossed $79.1 million domestically and $182.3 million worldwide. The film centers on a lawyer who is stalked by a former client who is released from prison. Scorsese was the director of the film.
The 1962 film starred Gregory Peck and Robert Mitchum. &nbsp;
The new series isn't the only item in the works for Scorsese or Spielberg.
Scorsese plans on shooting back-to-back films according to Variety. One would be about Jesus and the other about musician Frank Sinatra.
The Jesus film is based on the 1973 book "Life of Jesus" and Scorsese is considering independently financing it.
The Sinatra film is eying Leonardo DiCaprio as the singer and Jennifer Lawrence to play the singer's second wife, Ava Gardner. This film is drawing attention from several companies including Apple, but Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) is believed to be in the lead.
Spielberg is also working on a UFO film and on a series based on Napoleon Bonaparte. The series, which sources material from an unfinished film of Stanley Kubrick, will air on Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)-owned HBO.
Related Link: <a href="https://www.benzinga.com/general/entertainment/24/04/38024244/appletv-a-streaming-winner-new-survey-shows-platform-has-smallest-library-highest-rated-con">AppleTV+ A Streaming Winner? New Survey Shows Platform Has Smallest Library, Highest Rated Content</a>
Why It's Important: Even as producers of the new series and no involvement beyond that, the inclusion of Scorsese and Spielberg could help AppleTV+ have a new hit series that will get a lot of attention.
Given the previous source material and the names attached, it could be one of the most highly anticipated series for Apple as it nears.
Apple <a href="https://www.benzinga.com/24/03/37558754/apples-1b-gamble-on-3-blockbusters-analyzing-box-office-results-streaming-impact-and-oscar-nominatio">spent around $1 billion</a> on three blockbuster movies in 2023, with one being the Scorsese picture "Killers of the Flower Moon."
The film drew critical praise and was nominated for 10 Academy Awards, but was ultimately shut out. The film also grossed $67.9 million domestically and $156.9 million worldwide.
Apple has worked with Spielberg in the past as the film legend is a <a href="https://www.benzinga.com/general/entertainment/23/11/35717790/tom-hanks-steven-spielberg-back-together-for-world-war-ii-series-on-appletv-here-are-the-de">producer alongside</a> Tom Hanks on "Masters of the Air."
While it has a smaller content library, Apple's willingness to spend and grab big names along with key sports rights could make its streaming platform a must-subscribe for consumers.
Read Next: <a href="https://www.benzinga.com/general/entertainment/23/10/35430485/apple-hikes-subscription-prices-for-tv-arcade-bundle-will-also-get-more-expensive">Apple Hikes Subscription Prices For TV+, Arcade — Bundle Will Also Get More Expensive</a>
Photo: Steven Spielberg and Martin Scorsese in the press room at the 66th Annual Golden Globe Awards, photo by <a href="https://www.shutterstock.com/g/sbukley">s_bukley</a> via Shutterstock

Entertainment

AAPL

Sony Group Corporation American Depositary Shares

SONY

Steven Spielberg, Martin Scorsese Team Up On New Series For This Streaming Platform

Approximately one in 10 American adults report frequent marijuana use regardless of whether they live in a legal or non-legal state, confirming that state legalization does not significantly change consumption rates, according to a Gallup poll released Thursday.
This data begs a couple of questions: Does cannabis prohibition and criminalization effectively reduce consumption among adults? Has the war on drugs deterred marijuana consumption?
"The narrow gap in cannabis consumption among residents of states where it remains illegal compared with those in states where it is legal suggests that its criminalization does little to curtail its use among American adults," <a href="https://news.gallup.com/poll/642851/cannabis-greatest-among-lower-income-less-educated.aspx#:~:text=The%20narrow%20gap%20in%20cannabis,its%20use%20among%20American%20adults.">noted </a>Gallup.
That said, Gallup wrote: "Dovetailing with broadening legalization, the percentage of U.S. adults who report that they&nbsp;smoke marijuana&nbsp;has more than doubled in the past decade, climbing from 7% in 2013 to 17% in 2023. During that same period, the percentage reporting that they have tried it at least once has climbed from 38% to 50%.&#8221;
<h1 class="wp-block-heading">Cannabis Use Highest in Middle Atlantic Region</h1>
Reports of regular cannabis use vary across the U.S. Census divisions though the Middle Atlantic region showed the highest rates. While concluding that cannabis use is comparable between legal and non-legal states, the Gallup study found the highest usage rates were observed in New York, New Jersey and Pennsylvania, the latter being the only state that maintains adult-use prohibition. Then came East North Central divisions states of Wisconsin, Michigan, Illinois, Indiana and Ohio. 
The lowest usage rates, 7%, are reported in the East South Central states of Kentucky, Tennessee, Mississippi and Alabama. Followed by West North Central states of North Dakota, Minnesota, South Dakota, Nebraska, Iowa, Kansas and Missouri.
In the East North Central division, where marijuana is prohibited in some states, 11% of adults still use cannabis regularly — again indicating a nuanced relationship between legality and usage patterns.
"These differences are statistically meaningful" as they generally align with political identity.
<h1 class="wp-block-heading">Red Vs. Blue Vs. Green</h1>
People living in red states have somewhat lower regular usage rates than blue states. Regular use is reported by 10% of Democrats and independents, but it drops to 6% among Republicans.
Read the full Gallup poll <a href="https://news.gallup.com/poll/642851/cannabis-greatest-among-lower-income-less-educated.aspx#:~:text=The%20narrow%20gap%20in%20cannabis,its%20use%20among%20American%20adults.">HERE</a>
Photo: Elsa Olofsson On Unsplash

Cannabis

Government

Regulations

Cannabis Consumption, Legal Or Not In Your State: Everyone Seems To Be Consuming At Equal Rates, New Gallup Poll Finds

Florida-based EMI is a metal and millwork manufacturer of standard and customized fixtures, displays, and food equipment for the convenience store, grocery, and restaurant industries.&nbsp;As part of the transaction, the Company will welcome EMI&#39;s more than 300 employees to LSI
&quot;As outlined within our&nbsp;Fast Forward&nbsp;strategic plan, LSI intends to drive net sales growth by more than&nbsp;60%&nbsp;between fiscal year 2023 and fiscal year 2028, with approximately half of this growth supported by acquisition-related contributions,&quot; said&nbsp;James A. Clark, President and Chief Executive Officer.&nbsp;
Upon closing, the transaction will be immediately accretive to LSI on an adjusted earnings per share basis.

LYTS

LSI Industries Acquires Privately Held EMI Industries For An All-Cash Purchase Price Of $50M

The Colorado Senate has passed SB24-158, a bill that significantly tightens regulations on social media content related to <a href="https://www.benzinga.com/cannabis" target="_blank" rel="noreferrer noopener">cannabis</a>,<a href="https://www.benzinga.com/markets/psychedelics" target="_blank" rel="noreferrer noopener"> psychedelics</a> and hemp products. This bill, which has sparked a heated debate about free speech and digital regulation, could significantly alter the landscape of online content related to cannabis and other substances within the state.
<h3 class="wp-block-heading">Amendments And Opposition Highlight The Bill&#8217;s Complexity</h3>
<a href="https://www.benzinga.com/markets/cannabis/24/03/37830087/goodbye-to-weed-posts-in-colorado-lawmakers-target-social-media-promotion-of-cannabis-and-psyche">Initially introduced with </a><a href="https://www.benzinga.com/markets/cannabis/24/03/37830087/goodbye-to-weed-posts-in-colorado-lawmakers-target-social-media-promotion-of-cannabis-and-psyche" target="_blank" rel="noreferrer noopener">broader </a><a href="https://www.benzinga.com/markets/cannabis/24/03/37830087/goodbye-to-weed-posts-in-colorado-lawmakers-target-social-media-promotion-of-cannabis-and-psyche">implications</a>, the bill was <a href="https://s3-us-west-2.amazonaws.com/leg.colorado.gov/2024A/amendments/5C9383AE03C9962487258B00006D2613/SB158_J.001.pdf" target="_blank" rel="noreferrer noopener">amended</a> by State Sen. Chris Hansen (D) to allow the promotion of medical and retail cannabis to users over the age of 21, provided it complies with state laws. Despite these adjustments to refine the bill, its reach seems to remain extensive, applying to a wide array of substances.&nbsp;
Notably, the amended version specifies that &#8220;illicit substances&#8221; include <a href="https://www.benzinga.com/topic/hemp" target="_blank" rel="noreferrer noopener">hemp products</a> not classified as a tincture or cosmetic. These are defined as products possessing more than 1.25 milligrams of THC per serving, or those with a <a href="https://www.benzinga.com/topic/cbd">CBD</a> to THC ratio of less than 20 to 1.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Senator Michaelson Jenet and I worked hard to pass SB-158 out of the Senate today with a vote of 34-1. We urgently need better protections for children using social media. The companies are making record profits, but not doing enough to prevent access to illegal substances <a href="https://twitter.com/hashtag/coleg?src=hash&amp;ref_src=twsrc%5Etfw">#coleg</a> <a href="https://t.co/SnT2Hz5cKG">pic.twitter.com/SnT2Hz5cKG</a>
&mdash; Chris Hansen for Colorado (@Hansen4Colorado) <a href="https://twitter.com/Hansen4Colorado/status/1780695901410939387?ref_src=twsrc%5Etfw">April 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
With a 30–1 vote in favor, the Senate&#8217;s <a href="https://leg.colorado.gov/content/sb24-158vote55bd8e" target="_blank" rel="noreferrer noopener">decision</a> propels the <a href="https://leg.colorado.gov/bills/sb24-158" target="_blank" rel="noreferrer noopener">bill</a> into a potentially contentious future, as critics <a href="https://www.rstreet.org/commentary/colorado-bill-would-ban-users-from-talking-about-marijuana-and-medication-compromise-law-enforcement-investigations-and-stop-people-from-knowing-when-theyre-being-investigated/" target="_blank" rel="noreferrer noopener">argue</a> it infringes on the right to discuss legal and benign substances online.
Voices like the R Street Institute&#8217;s Shoshana Weismann have called out the legislation for its potential to limit discussions on common medications, labeling such restrictions as &#8220;asinine,&#8221; <a href="https://www.marijuanamoment.net/colorado-senate-passes-bill-that-could-ban-social-media-users-who-post-positively-about-drugs-including-legal-psychedelics/" target="_blank" rel="noreferrer noopener">according</a> to Marijuana Moment. Meanwhile, proponents of plant and fungi-based medicines fear the bill could stifle educational efforts and dialogue on these alternative treatments.
<h3 class="wp-block-heading">Bill's Next Steps Amid Legalization Support</h3>
With the bill&#8217;s enactment, social media platforms would be tasked with updating their policies by July 2025, under the watchful eye of the <a href="https://www.benzinga.com/markets/cannabis/24/01/36617725/12-state-attorneys-general-to-dea-reschedule-marijuana-to-defend-public-safety-cannabis-stocks-j" target="_blank" rel="noreferrer noopener">Colorado attorney general</a>. Now under the consideration of Colorado&#8217;s House Committee on Education, the bill's discussion unfolds as the state enjoys <a href="https://www.benzinga.com/markets/cannabis/24/04/38320660/colorado-residents-are-happy-with-legal-weed-a-decade-later-they-especially-praise-positive-econ" target="_blank" rel="noreferrer noopener">broad popular support for the legal regulation of cannabis</a>.

Psychedelics

Markets

Colorado Senate Approves Controversial Bill Restricting Social Media Posts On Substances Like Legal Hemp, Psychedelics

Earnings

BANF

BancFirst Q1 Sales $151.00M Beat $147.54M Estimate

The FILO Term Loan Facility significantly enhances the Company&#39;s liquidity position and is incremental to the borrowing capacity within the Company&#39;s current&nbsp;$900 million&nbsp;asset-based revolving loan facility.

Big Lots Increases Its Borrowing Capacity By Up To $200M With New 'First In, Last Out' Term Loan Facility

IPOs

TRSG

Tungray Technologies Prices IPO Of 1.25M Class A Ordinary Shares At $4 Per Share; To Commence Trading On Nasdaq Capital Market Under Ticker Symbol 'TRSG' On April 19

<h1 class="wp-block-heading">Top Stories for April 18, 2024:</h1>
<ol>
<li>Alcoa Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) <a href="https://www.benzinga.com/wiim/24/04/38309731/alcoa-shares-are-trading-higher-following-better-than-expected-q1-financial-results">reported first-quarter losses</a> of 81 cents per share with revenues of $2.6 billion, slightly above the expected $2.56 billion.&nbsp;</li>
</ol>
In the alumina segment, revenues rose by 6% due to higher prices and increased shipments, while the aluminum segment saw a 3% revenue drop from lower prices and shipment timing.&nbsp;
Alumina production fell by 4% to 2.67 million metric tons and aluminum production remained stable at 542,000 metric tons.&nbsp;
Alcoa also finalized acquiring Alumina Limited and projects full-year alumina production of 9.8 million to 10 million metric tons and shipments of 12.7 million to 12.9 million metric tons.
<ol start="2">
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) released its 2023 Sustainability and Taxes &amp; Royalties Reports, marking 20 years of its sustainability efforts.&nbsp;</li>
</ol>
Key achievements include expanding its Fatality Risk Management program, completing over 650,000 safety verifications, aligning facilities with the Tailings Management Standard and enhancing workplace inclusivity.&nbsp;
The company increased female leadership to 33%, reduced freshwater use by 31% since 2018 and met a $20 million commitment to support communities affected by COVID-19.&nbsp;
Newmont has been ranked as the top gold mining company on the Dow Jones Sustainability Index for nine years and is also highly ranked on 3BL&#8217;s Corporate Citizens list.
Also Read:<a href="https://www.benzinga.com/topic/mining"> </a><a href="https://www.benzinga.com/news/24/04/38313888/new-canadian-budget-deemed-mixed-bag-for-mining-sector">New Canadian Budget Deemed Mixed Bag For Mining Sector</a>
<ol start="3">
<li>Foremost Lithium Resource &amp; Technology Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMST#NASDAQ">FMST</a>) announced its participation in the 2024 Planet MicroCap Showcase on May 1 to 2 at the Paris Hotel &amp; Casino in Las Vegas.&nbsp;</li>
</ol>
President and CEO Jason Barnard will present on May 1 and hold investor meetings on May 2.
<ol start="4">
<li>Nucor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) appointed Nicole B. Theophilus as executive vice president of Talent and Human Resources, starting April 29, 2024, to lead the company's talent development and HR strategy.</li>
</ol>
<ol start="5">
<li>Scotiabank Maintained its Sector Underperform rating on Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) but raised its price target to $55.</li>
</ol>
Now Read:<a href="https://www.benzinga.com/"> </a><a href="https://www.benzinga.com/markets/commodities/24/04/38295033/rio-tintos-next-chief-commercial-officer-says-building-mines-is-better-than-buying-heres-how-">Rio Tinto&#8217;s Next Chief Commercial Officer Says Building Mines Is Better Than Buying: Here&#8217;s How Long It Takes</a>
Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> to get connected with the Benzinga community!
Image was created using artificial intelligence.

Commodities

FMST

SCCO

Alcoa Reports Q1 Results; Newmont's 2023 Sustainability Report; Foremost Lithium To Attend Planet MicroCap Showcase And More: Thursday's Top Mining Stories

BancFirst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) reported quarterly earnings of $1.50 per share which beat the analyst consensus estimate of $1.39 by 7.91 percent. This is a 12.79 percent decrease over earnings of $1.72 per share from the same period last year.

BancFirst Q1 EPS $1.50 Beats $1.39 Estimate

ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) has outperformed the market over the past 5 years by 4.12% on an annualized basis producing an average annual return of 15.39%. Currently, ATI has a market capitalization of $6.45 billion. 
Buying $100 In ATI: If an investor had bought $100 of ATI stock 5 years ago, it would be worth $200.47 today based on a price of $51.83 for ATI at the time of writing.
<h3>ATI's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713475861_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning ATI Stock In The Last 5 Years

The Company&#39;s current Senior Vice President of Corporate Finance &amp; Strategy,&nbsp;Stephen Zsigray, will succeed him at that time to become Ashford Trust&#39;s President and Chief Executive Officer.&nbsp;

Management

Ashford Hospitality Trust Says Rob Hays, Current President And CEO, Will Be Stepping Down Effective June 30, 2024; Stephen Zsigray Named As Successor

Masheed Saidi had advised the Board that she does not intend to stand for reelection. In addition,&nbsp;Kenneth Moore, the Chair of the Board, has informed the Board of his intention to retire effective as of the Annual Meeting and he will therefore not stand for reelection. As a result, following the Annual Meeting, Algonquin&#39;s Board will continue to be comprised of nine directors.&nbsp;
Starboard Value LP, which own approximately&nbsp;9.0%&nbsp;of Algonquin&#39;s outstanding common shares,&nbsp;has withdrawn its previously-announced director nominations for election and agreed to support the Company&#39;s nominees for election at the Annual Meeting.
Starboard and the Company have also entered into a non-disclosure agreement for purposes of sharing information and having discussions relating to the pursuit of a sale of the Company&#39;s renewable energy business and the Company&#39;s CEO search.

Algonquin Power & Utilities Enters Into Cooperation Agreement With Starboard; Adds Brett Carter And Christopher Lopez To Board

Arcline Investment Management LP is acquiring Kaman in a deal expected to close on April 19, pending final closing conditions.&nbsp;

KAMN

Cohen & Steers To Join S&P SmallCap 600, Replacing Kaman, Effective Prior To Opening Of Trading On April 23

FLFV

Blank Check Company Feutune Light Acquisition Reports Extension Of Deadline For Initial Business Combination To May 21, 2024

The temporary closing of the Kermit facility will have no impact on the timing or cost of the Dune Express construction. The company said it is&nbsp;assessing the cost to repair the feed system and reviewing the financial impact of the incident.

AESI

Atlas Energy Solutions Provides Update On Mechanical Fire Occurred At Mine In Kermit, Texas; Says Fire Primarily Impacted The Feed System

Western Alliance Bancorporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) reported its first-quarter financial results after the bell Thursday. Here's a <a href="https://www.benzinga.com/pressreleases/24/04/b38324109/western-alliance-bancorporation-reports-first-quarter-2024-financial-results">look at the details. </a>
The Details: Western Alliance reported quarterly earnings of $1.60 per share, missing the consensus estimate of $1.66 by 3.61% and representing a 30.43% decrease from the same period last year. 
The company reported quarterly sales of $728.8 million which beat the analyst consensus estimate of $697.04 million by 4.56% and represents a 32.05% increase over sales of $551.9 million year-over-year. 
Western Alliance delivered a return on tangible common equity of 14.5% and tangible book value per share climbed 13.8% year-over-year to $47.30 with a CET 1 ratio of 11%.
&#8220;Western Alliance delivered strong first quarter results with continued robust business and deposit momentum that allowed us to largely complete our balance sheet repositioning efforts, while maintaining stable asset quality,&#8221; said Kenneth A. Vecchione, CEO of Western Alliance.
&#8220;Quarterly deposit growth of $6.9 billion enhanced our liquidity profile, drove the loan-to-deposit ratio down to 81.5%, and allowed us to repay $1.0 billion of borrowings,&#8221; Vecchione added.
Western Alliance will host a <a href="https://www.benzinga.com/pressreleases/24/04/b38173227/western-alliance-bancorporation-announces-first-quarter-2024-earnings-release-date-conference-call">conference call</a> Friday at 12 p.m. ET to discuss the results. 
Related News: <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock">What&#8217;s Going On With Arm Holdings Stock?</a>
WAL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Western Alliance shares are down 3.66% after-hours at $53.70 at the time of publication Thursday.
Photo: Robert Owen-Wahl from Pixabay

After-Hours Center

Movers

Western Alliance Reports Mixed Q1 Results: Earnings Miss, Revenue Beats

Frontier Communications Parent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>) shares are experiencing weakness in Thursday&#8217;s after-hours session after the company disclosed an operational disruption <a href="https://www.benzinga.com/topic/cyber-attacks">due to a cyberattack</a>. 
What Happened: In a regulatory filing released after the bell on Thursday, Frontier said it detected a third party had gained unauthorized access to portions of its information technology business on April 14. 
After detecting the unauthorized access, the company initiated its cyber incident response protocols, including shutting down certain systems, which resulted in &#8220;an operational disruption that could be considered material.&#8221;
&#8220;As of the date of this filing, the Company believes it has contained the incident and has restored its core information technology environment and is in the process of restoring normal business operations,&#8221; the company said in the filing.
Based on internal investigations, Frontier believes the culprit was likely a cybercrime group. The company noted that the attackers gained access to personally identifiable information. 
Frontier has notified law enforcement, but it doesn&#8217;t believe the incident is &#8220;reasonably likely to materially impact&#8221; the company&#8217;s financial results or operations. The investigation is currently ongoing. 
Frontier is due to report <a href="https://www.benzinga.com/calendars/earnings">first-quarter financial results</a> before the market opens on May 3. The company is expected to report a loss of 7 cents per share on revenue of $1.436 billion, according to analyst estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">Netflix Q1 Earnings Highlights: Revenue Beat, EPS Beat, 9.33 Million Paid Subs Added, Ad-Tier Plan Update And More</a>
FYBR Price Action: Frontier shares were down 3.59% after hours at $21.76 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

FYBR

Frontier Communications Stock Slides After Company Reveals Cyberattack: The Details

Community West Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWBC#NASDAQ">CWBC</a>) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.45 by 31.11 percent. This is a 14.81 percent increase over earnings of $0.27 per share from the same period last year.

Earnings Misses

CWBC

Community West Bancshares Q1 EPS $0.31

Martin A. Kropelnicki, Group Chairman &amp; CEO, said, &quot;Although the CPUC rejected our application to include capital costs in our PFAS balancing account, we will proceed with our plans to construct treatment to meet the new federal water quality standard.&quot;
Additionally, Group has filed lawsuits to hold PFAS manufacturers financially responsible for the costs of testing and treatment, and is pursuing grants where available, to reduce the financial impact on its customers.

California Water Service Reports CPUC Dismissal Of Request To Include Capital Costs In Its PFAS Balancing Account; Reaffirms Commitment To Investing An Estimated $215M In PFAS Treatment

Tracking Baker Brothers Portfolio - Q2 2023 Update

Kala Pharmaceuticals GAAP EPS of -$3.41 misses by $1.26

Wedbush analyst Andreas Argyrides reiterated a Buy rating on Kala Pharmaceuticals (KALA – Research Report) today and set a price target of $22.00. ...

Kala Pharmaceuticals: Promising Pipeline and Financial Stability Indicate Strong Market Position – An Analysis

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on KALA stock, giving a Buy rating on November 14. Yi Chen has given his Buy ra...

Promising Financial Stability and Clinical Trials Prospects Propel Yi Chen's Buy Rating for Kala Pharmaceuticals

These Healthcare stocks are trading higher:-Clearmind Medicine Inc (CMND) stock is trading at $5.28, an increase of $1.45, or 37.86%, on high volume.  Clearmind Medicine Inc gets a Sentiment Score of Bearish from InvestorsObserver.  -KALA BIO Inc (KALA) stock is trading at $8.40, a gain of $1.91, or 29.35%, on high volume.

Healthcare Stocks Making Moves Tuesday: CMND, KALA, TVTX, DRIO, IBIO, REPL, MYNZ, SEEL

A rating of 82 puts KALA BIO Inc (KALA) near the top of the Biotechnology industry according to InvestorsObserver. KALA BIO Inc's score of 82 means it scores higher than 82% of stocks in the industry. KALA BIO Inc also received an overall rating of 63, putting it above 63% of all stocks. Biotechnology is ranked 50 out of t

Should Biotechnology Stock KALA BIO Inc (KALA) Be in Your Portfolio Wednesday?

Kala Pharmaceuticals Inc (KALA) just unveiled an update. KALA BIO, Inc. has released a new corporate presentation focusing on ophthalmology innovat...

KALA Pharmaceuticals Spotlights Ophthalmology Advances

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kala Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kala-stock-quote/">KALA</a>) just reported results for the fourth quarter of 2023.<ul><li>Kala Pharmaceuticals reported earnings per share of -$3.18. This was above the analyst estimate for EPS of -$3.62.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/kala-stock-earnings-kala-pharmaceuticals-for-q4-of-2023/">KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023

Kala Pharmaceuticals (KALA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H....

Buy Rating on Kala Pharmaceuticals Amidst Positive Clinical Developments and Strong Financial Position

ABCL

ACAD

ACHL

AKRO

ARAV

ARGNF

ARGX

AVTE

BCRX

BEIGF

BGNE

BMEA

BMRN

CABA

CERS

CMND

DRIO

HOOK

IBIO

IMCR

IMTX

INCY

KYMR

MDGL

MYNZ

NLTX

NRIX

REPL

ROIV

RYTM

SEEL

SGEN

TCRX

TLIS

TSVT

TVTX

Events

Press Releases

Sidoti Events, LLC's Virtual August Micro-Cap Conference

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Limbal Stem Cells Deficiency Market Size in the 7MM was approximately USD 2,600 million in 2022, estimates DelveInsight | Holostem, Kala Pharmaceuticals, RHEACELL GmbH & Co. KG, FGK Clinical Research

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Limbal Stem Cells Deficiency Market Size in the 7MM was approximately USD 2,600 million in 2022, estimates DelveInsight | Holostem, Kala Pharmaceuticals, RHEACELL, FGK Clinical Research

Health Care

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update